Anti-Human OX40L (Oxelumab) Fc Muted
|Amount :||500 µg|
|Isotype :||Human IgG1k|
|Purification :||>=95% monomer by analytical SEC|
|Content :||Concentration : >= 5.0 mg/ml
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
|Storage condition :||Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.|
|Alternative Name :||TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B|
|Immunogen Information :||Original antibody raised against Human OX40L|
Expression Host : HEK-293
Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of this recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only.
Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.
Endotoxin : <= 1.0 EU/mg as determined by the LAL method
The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is <= 0.25 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.